Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference40 articles.
1. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63–8.
2. Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d'Ettorre G, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19(4):732–9.
3. Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL. Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. Antimicrob Agents Chemother. 2015;60(3):1600–7.
4. Matsumoto T, Takesue Y, Iwata S, Ueda T, Uchiyama K, Kobayashi K, et al. Practical guidelines for the management and treatment of infections caused by MRSA, 2019 edition. Tokyo, Japan: Japanese Society of Chemotherapy/ Tokyo, Japan: the Japanese Association for Infectious Diseases; 2019. http://www.chemotherapy.or.jp/guideline/guideline_mrsa_2019.pdf. Accessed 14 October 2020, Japanese.
5. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献